Regeneron (REGN) balance sheet and financial health

Biotechnology · NASDAQ · Health Care

$957.76 +0.56% Close Nov 17, 2026 Live

TrendArc score 68 of 100 · Health 7.7 · Momentum 9.2 · Moat 6.5 · scored Nov 17, 2026 · How the score works

Cash and short-term investments less borrowings, September 30, 2026

$7.3 billion more cash than borrowings

Regeneron held $9.3 billion of cash and short-term investments against $2.0 billion of borrowings on September 30, 2026. In the fiscal year to December 2025 its operating income covered its interest 81.7 times.

Borrowings to equity

0.06

$1.99B of borrowings on $33.5B of equity, Sep 2026

Interest cover

81.7x

operating income over interest, fiscal year to December 2025

Return on invested capital

22.0%

latest quarter to September 2026, annualised; the stock card's measure

Cash and borrowings at each fiscal year end

$5.00B$10.0B$15.0B2016201720182019202020212022202320242025Cash and short-terminvestments $8.61BBorrowings $1.99B$5.00B$10.0B$15.0B20172019202120232025Cash and short-term investments $8.61BBorrowings $1.99B

What stands out

  • Its return on invested capital, as the stock card measures it, had a median of 16.2% over the last five years.

Each sentence is written by a fixed rule from the figures on this page.

What the balance sheet holdsSeptember 30, 2026

Assets $44.4BCash and short-term investments$9.30BReceivables$7.58BInventory$2.89BOther current assets$1.02BLong-term investments$9.56BProperty, goodwill and other$14.1BFunded by $44.4BBorrowings$1.99BOther liabilities$8.92BShareholders' equity$33.5BAssets $44.4BCash and short-term investments$9.30BReceivables$7.58BInventory$2.89BOther current assets$1.02BLong-term investments$9.56BProperty, goodwill and other$14.1BFunded by $44.4BBorrowings$1.99BOther liabilities$8.92BShareholders' equity$33.5B

"Other liabilities" is total liabilities less borrowings; "Property, goodwill and other" is total assets less the current assets and long-term investments.

Balance sheet, the last 10 fiscal year ends

In billions of US dollars, at each fiscal year end, named by the month it ended; the first column is the newest balance sheet on file. Borrowings are bonds, notes, loans and commercial paper; lease liabilities, operating and finance, are shown apart.
Fiscal year endLatest
Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Assets
Cash and short-term investments9.38.69.010.87.75.73.63.22.81.41.0
Receivables7.65.76.25.75.36.04.12.82.22.01.6
Inventory2.93.23.12.62.42.01.91.41.20.70.4
Other current assets1.00.50.30.40.40.30.20.30.20.20.1
Total current assets20.818.018.719.515.914.09.87.76.44.33.2
Long-term investments9.610.38.95.46.66.83.13.31.81.50.9
Total assets44.440.637.833.129.225.417.214.811.78.87.0
Liabilities and equity
Current liabilities6.24.43.93.43.13.92.72.11.41.11.2
Borrowings2.02.02.02.02.02.02.00.00.0——
Lease liabilities—1.01.00.8———0.7———
Total liabilities10.99.38.47.16.66.76.13.73.02.62.5
Shareholders' equity33.531.329.426.022.718.811.011.18.86.14.4
Financial health
Cash less borrowings7.36.67.08.95.83.71.63.22.8——
Borrowings to equity0.060.060.070.080.090.110.180.000.00——
Interest cover—81.7x72.3x55.4x79.8x156x62.9x73.2x89.9x82.9x185x

Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.

Regeneron against its peers

CompanyCash less borrowingsBorrowings to equityInterest coverReturn on invested capital
RegeneronREGN +$7.31B 0.06 81.7x 22.0%
IncyteINCY +$3.86B 0.00 624x -55.4%
Vertex PharmaceuticalsVRTX +$1.81B 0.22 314x 9.9%
ModernaMRNA +$1.62B 0.52 — 5.9%
BiogenBIIB -$6.39B 0.41 — -0.3%
Gilead SciencesGILD -$19.8B 2.01 9.8x 26.4%
AmgenAMGN -$40.8B 3.76 3.3x 23.4%

Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.

Next

Follow Regeneron with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Regeneron from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.